58 results about "High-density lipoprotein" patented technology

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention discloses bifidobacterium adolescentis for relieving estrogen-related metabolic disorder and obesity and application thereof, and belongs to the technical field of microorganisms. The bifidobacterium adolescentis CCFM1506 screened by the invention can effectively improve ovariectomized individual estrogen disorder symptoms, obviously slow down the weight increase speed and weight increment of estrogen disorder individuals, increase the expression quantity of serum estradiol, CYP11A1 and ERalpha in adrenal gland and the high-density lipoprotein content in serum, reduce the total cholesterol and glucose level and improve the ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized abnormal glucose and lipid metabolism is adjusted; the invention has the advantages of simple preparation method and wide application prospect, can be used for preparing medicines for relieving or treating estrogen-related metabolic disorders and obesity, and can be used for preparing health-care products beneficial to controlling in-vivo fat and maintaining the health level of blood fat, and has obvious physiological effects and wide application prospects, and can be used for preparing the medicines for relieving or treating the estrogen-related metabolic disorders and obesity and preparing health-care products beneficial to controlling in-vivo fat and maintaining the health level of blood fat. A new thought and a new basis are provided for developing functional foods or medicines based on the probiotics.

The present invention relates to nanoparticles complexed with biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) carrying biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and / or therapeutic settings).

The invention discloses a composition with an auxiliary blood fat reducing effect as well as a preparation method and application thereof, and relates to the technical field of medicines. In the composition disclosed by the invention, the hawthorn, the lotus leaf, the mulberry leaf and the algae oil are mutually matched for use and have a synergistic effect, so that the effects of remarkably reducing the body weight, reducing the content of low-density lipoprotein, the content of Apo-B and the content of GLU in blood and improving indexes of high-density lipoprotein and Apo-A1 are achieved. The composition is applied to preparation of the blood fat reducing medicine and / or health food, and the blood fat reducing effect is stable.

The present invention relates to nanoparticles associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and / or therapeutic settings).

The invention relates to a method for constructing a preeclampsia prediction model by using clinical laboratory data and a related application thereof. Specifically, the preeclampsia risk prediction model is constructed based on a plurality of clinical indexes of pregnant women, a plurality of clinical laboratory data and insulin growth binding factor binding protein 1 and / or placental growth factors. The clinical laboratory data comprises leukocyte count and / or urine protein, and further comprises any one or combination of platelet count, monocyte proportion, glutamic-straw / glutamic-pyruvic transaminase ratio, glutamyltranspeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Meanwhile, the sensitivity of the prediction model is 88.0% when the specificity of early eclampsia is 85.04% and the sensitivity of the prediction model is 62.5% when the specificity of late eclampsia is 85.04% in a complete independent verification set, and the detection performance of the prediction model is higher than that of the current detection performance.

Provided are molecular hooks that are capable of tethering a ribonucleic acid (RNA) of interest to a high-density lipoprotein (HDL) molecule. Also provided are methods of RNA delivery to cells and organisms using the molecular hooks of the present disclosure. Such methods provide several advantages including the ability to deliver the RNA of interest to tissues behind the blood-brain barrier, and not requiring extreme cold temperatures for storage or transport.

The invention relates to the technical field of anti-tumor bionic nanomaterials, and discloses a preparation method and application of tumor-bacterial membrane chimeric nanoparticles, and the preparation method comprises the following steps: carrying out rotary evaporation on dimyristoyl phosphatidylcholine and cholesterol oleate to obtain an HDL rotary evaporation film; mixing the tumor cell membrane with the bacterial membrane to obtain a tumor-bacterial mixed membrane; pre-mixing apolipoprotein ApoA-1 with the tumor-bacteria mixed membrane, and adding the mixed solution into a container containing an HDL rotary evaporation membrane for hydration and reconstruction to obtain a crude suspension; and carrying out ultrafiltration purification on the crude suspension to obtain the tumor-bacterial membrane chimeric nanoparticles. The tumor cell membrane and the bacterial membrane are co-loaded on the high-density lipoprotein, so that the two membrane components can be co-delivered to the dendritic cells to induce maturation of the dendritic cells, are accumulated in tumors and drainage lymph nodes in vivo, activate CD8 + T cell response and have an inhibition effect on tumor growth.

The invention discloses a novel application of emodin and a high-density lipoprotein analogue in preparation of a medicine. The high-density lipoprotein analogue comprises apolipoprotein A-1 single mimetic peptide and natural phospholipid. The invention has the advantages of long-term stability and no immunogenicity and organ toxicity risk, thereby providing a clinically convertible solution for precise treatment of nerve injury.

The application discloses a composition for improving blood lipid metabolism, which comprises the following raw materials: sweet cinnamon powder, rhodiola powder, roxburgh rose powder and curcuma zedoaria powder. The preparation method of the composition for improving blood lipid metabolism comprises the following steps: screening the sweet cinnamon powder, the rhodiola powder, the roxburgh rose powder and the curcuma zedoaria powder respectively, mixing them uniformly to obtain mixed powder; adding sterile deionized water into the mixed powder to obtain a mixed solution; adding a complex enzyme into the mixed solution for enzymolysis; after the enzymolysis is completed, the enzyme is inactivated, filtration is conducted, and the filtrate is freeze-dried to obtain the composition for improving blood lipid metabolism. The plant powder is subjected to mixed enzymolysis through multiple enzymes, the natural active substances in the plant powder are enriched, and the types of the enzymolysis products are enriched, so that the total cholesterol, the triglyceride and the low-density lipoprotein content in blood can be reduced, and the high-density lipoprotein content in blood can be increased.

Provided are molecular hooks that are capable of tethering a protein of interest to a high-density lipoprotein (HDL) molecule. Also provided are methods of intracellular protein delivery to cells and organisms using the molecular hooks of the present disclosure. Such methods provide several advantages including the ability to intracellularly deliver the protein of interest to tissues behind the blood-brain barrier, and not requiring extreme cold temperatures for storage or transport.

The invention belongs to the technical field of medical risk assessment, and provides a fibrosis metabolism related steatohepatitis risk assessment system. Comprising a data acquisition module configured to determine candidate prediction indexes; the primary screening module is configured to perform single-factor logistic regression analysis on the candidate prediction indexes to determine key prediction indexes of fibrosis metabolism related steatohepatitis; the secondary screening module is configured to screen out four independent predictive factors from key predictive indexes of fibrosis metabolism related steatohepatitis through stepwise multiple regression analysis; and the model training module is configured to train the constructed multi-factor logistic regression model based on the screened four independent predictive factors. According to the method, four indexes of aspartate transaminase, alanine transaminase, triglyceride and high-density lipoprotein cholesterol are integrated, a fibrosis MASH evaluation and prediction model for obese people is constructed, and the evaluation performance is better.

The invention provides pediococcus acidilactici XZFMCC101.23156, a microbial preparation, an antibacterial composition and application of the pediococcus acidilactici XZFMCC101.23156, and belongs to the technical field of functional microorganisms. The preservation number of the pediococcus acidilactici XZFMCC101.23156 is GDMCC No: 66860, and the pediococcus acidilactici XZFMCC101.23156 can be used as a functional microbial agent to be applied in vivo to improve diseases such as hyperlipidemia and the like, and can also achieve the effect of reducing body weight. The result of the embodiment shows that the culture supernatant of the pediococcus acidilactici XZFMCC101.23156 can effectively reduce the total cholesterol, the triglyceride, the low-density lipoprotein and the high-density lipoprotein in a rat body. The pediococcus acidilactici XZFMCC101.23156 provides a new way for the development of oral probiotic preparations and the preparation of foods, drinks, health care products and medicines with the function of degrading cholesterol.

Disclosed herein are spherical high-density lipoprotein-like nanoparticles (HDL-NP) having a soft material core (e.g., a lipid-conjugated inorganic core). Also disclosed herein are methods for synthesizing the spherical HDL-NPs. Also disclosed herein are methods for treating disorders such as cardiovascular disease, cancer, inflammatory disorders or reducing NF-kB activity with the spherical HDL-NPs.

The application discloses a kind of traditional Chinese medicine preparation for treating hyperlipidemia, which is prepared from the following raw medicinal materials: radix codonopsis 10-20 g, astragalus 25-35 g, gynostemma pentaphyllum 10-20 g, atractylodes 10-20 g, zanthoxylum 3-8 g, monascus 10-15 g, and galangal 10-20 g. When treating, it is orally taken, one dose per day, taken twice, taken half an hour after breakfast and dinner, and continuously taken for 4 weeks as a treatment course. The traditional Chinese medicine preparation for treating hyperlipidemia has the advantages that it is helpful to improve hyperlipidemia, and the serum total cholesterol, triglyceride, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and other indicators of patients after treatment are obviously better than those of the control group (oral atorvastatin), with statistical significance (P<0.05). The traditional Chinese medicine preparation for treating hyperlipidemia has the advantages of remarkable curative effect, good safety, low price and simple prescription, and has high clinical popularization value.

The present invention is related to the field of targeted drug delivery. In particular, the particles and compositions described herein are used to deliver drugs to treat the diseases and conditions of interest. These particles and compositions include, but are not limited to, the lipopeptide complexes that mimic human high-density lipoproteins but contain apolipoprotein fragments or combination thereof.

Conventionally, it has been necessary to collect blood of a subject and perform biochemical analysis to measure LDL cholesterol and HDL cholesterol. However, in this method, a needle or the like needs to be invasively inserted into the skin of the subject, which causes a psychological or physical burden on the subject. According to the present invention, it is possible to non-invasively estimate cholesterol based on attribute information and / or non-invasive biological information of a predetermined user by generating a cholesterol estimation model by machine learning based on attribute information, non-invasive biological information, and blood examination data acquired from a plurality of subjects in advance.

The present disclosure is directed to the treatment of ischemic heart disease and clinical conditions associated with ischemic heart disease. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in cardioprotective effects against acute myocardial infarction, such as a decrease in circulating triglycerides, total cholesterol, and low-density lipoproteins, and an increase in the ratio of high-density lipoprotein to total cholesterol.

The present invention relates to obeticholic acid:or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.

The invention discloses a polysaccharide composition for treating chronic alcoholic liver injury and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is prepared by crushing phellinus linteus linteus, bolete, morchella and cordyceps militaris, mixing the crushed materials according to a mass ratio of 4: 2: 2: 2, performing water ultrasonic extraction, and performing hot water extraction. The polysaccharide composition can reduce fat vacuolation and hepatocyte swelling in the liver, inhibit expression of liver function related enzymes such as ALT and AST, improve secretion of blood fat such as total cholesterol, triglyceride and high-density lipoprotein cholesterol and reduce expression of inflammatory factors such as IL-1beta and TNF-alpha in the liver, and the effect of the polysaccharide composition is better than that of single polysaccharide. The polysaccharide composition can relieve liver injury caused by long-term drinking and achieve the effects of dispelling the effects of alcohol and protecting the liver.

The invention relates to pegylated recombinant high-density lipoprotein nanoparticles, which have the effect of preventing or treating neurodegenerative diseases. Specifically, the present invention relates to a nanoparticle and a method for preparing the same, in which a polyethylene glycol-lipid (PEG-lipid) or a derivative thereof is added during the preparation of a fluid containing a hydrophobic substance and a fluid containing a hydrophilic substance, thereby protecting a phospholipid layer of the prepared nanoparticle by PEG, and to a method for preparing the same. The pegylated nanoparticles not only maintain the original blood-brain barrier-crossing delivery ability, but also have the ability to avoid a clearance mechanism caused by in-vivo immune action, thus having excellent stability, and exhibiting a long-term pharmacological effect on the basis of the high in-vivo circulation ability thereof. Therefore, the compound can be effectively used as a drug or a drug delivery vehicle.

The invention discloses a lactobacillus plantarum BH52, which has a preservation number of CCTCC (China Center for Type Culture Collection) NO: M 20251294, and is characterized in that the preservation number of the lactobacillus plantarum BH52 is CCTCC NO: M 20251294. The strain is separated from human intestinal tracts, and is identified as plant lactobacillus through 16S rRNA (ribosomal Ribonucleic Acid) sequencing. Experiments show that the BH52 strain can efficiently degrade cholesterol and uric acid, significantly increase high density lipoprotein (HDL is increased by 29.8%), and improve kidney function indexes. The gastric acid resistance (the survival rate is 91.5% when the pH value is 3.0) and the cholate resistance (the survival rate is 94.3% when the cholate is 0.3%) are excellent, and the safety is high. The strain can be independently used or compounded for preparing functional foods or medicines for reducing blood fat and uric acid.

The application discloses a strain of Bifidobacterium adolescentis for relieving estrogen-related metabolic disorders and obesity and an application thereof, and belongs to the technical field of microorganisms. The Bifidobacterium adolescentis CCFM1506 screened by the application can effectively improve the symptoms of estrogen disorders of ovariectomized individuals, significantly slow down the weight growth rate and weight increment of individuals with estrogen disorders, increase the expression amounts of serum estradiol, CYP11A1 and ERa in adrenal glands and the high-density lipoprotein content in serum, reduce the total cholesterol and glucose levels, adjust abnormal glucose and lipid metabolism, increase SCFA in colon contents, relieve menopausal syndrome caused by the decrease of estrogen, and can be used for preparing medicines for relieving or treating estrogen-related metabolic disorders and obesity, or health care products for helping to control fat in the body and maintain the healthy level of blood lipids. The significant physiological effect and wide application prospect provide a new thought and new basis for developing functional foods or medicines based on probiotics.

The application discloses a method for constructing a hyperlipidemia-resistant rat model, and belongs to the technical field of experimental animal model construction. S1, basic population screening: abnormal lipid metabolism rats are selected, and the rats are fed with high-fat feed at the age of 4 weeks, and the feeding is continuously performed for 4 weeks; S2, blood lipid detection and preliminary screening: the animals are fasted for 12h, blood is taken from the submandibular vein, serum is separated by centrifugation at 3000r / min for 10min, and the total cholesterol, triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol contents are detected by using an automatic biochemical analyzer; S3, paired reproduction and subculture: 30 male rats and 30 female rats are selected, and the rats are paired for reproduction at a ratio of 1:1 to obtain F1 generation; S4, inbreeding and stabilization: the F2-F4 generation rats are repeatedly fed, detected, screened and paired for reproduction according to steps S1-S3, and the F4 generation hyperlipidemia-resistant rat model is obtained through inbreeding, and the technical effect of obtaining the hyperlipidemia-resistant rat model which is stable in phenotype and can be inherited and subcultured is achieved through the combination of hybridization screening and inbreeding.

The present application relates to the biomedical technology field, and particularly to a blood biomarker for early coronary heart disease diagnosis, and a screening method and application thereof.The blood biomarker comprises blood clinical indicators and plasma metabolome characteristics, the blood clinical indicators comprise direct bilirubin, aspartate aminotransferase and high-density lipoprotein, and the plasma metabolome characteristics comprise pyroglutamic acid, N-formyl-L-methionine, hypoxanthine, pinobetsin and L-valyl-alanine.The present application not only uses plasma metabolome characteristics, but also incorporates blood clinical indicators through blood routine and blood biochemical detection, compared with other methods, more comprehensively reflects the physiological and pathological state of the body, reduces the possibility of result deviation, and therefore adopts multi-dimensional blood biomarkers, which can more accurately predict the risk of early coronary heart disease.In addition, the adoption of multi-dimensional blood biomarkers can also improve the specificity and sensitivity of screening and diagnosis of early coronary heart disease.

The present invention relates to: reconstituted high-density lipoprotein nanoparticles comprising cholesterol; and a composition for preventing or treating Alzheimer's disease and cancer, the composition comprising the nanoparticles. Specifically, the reconstituted high-density lipoprotein nanoparticles comprising cholesterol according to the present invention have an excellent cell influx rate and promote cholesterol efflux from cells, thus having a cancer cell killing effect, and can therefore be used for preventing or treating cancer.

The present application belongs to the technical field of medical risk assessment, and proposes a fibrosis metabolism related fatty hepatitis risk assessment system. It comprises: a data acquisition module configured to determine candidate prediction indicators; a primary screening module configured to perform single-factor logistic regression analysis on the candidate prediction indicators to determine key prediction indicators of fibrosis metabolism related fatty hepatitis; a secondary screening module configured to screen four independent prediction factors from the key prediction indicators of fibrosis metabolism related fatty hepatitis through stepwise multiple regression analysis; and a model training module configured to train a constructed multi-factor logistic regression model based on the four screened independent prediction factors. The present application integrates four indicators of aspartate aminotransferase, alanine aminotransferase, triglyceride and high-density lipoprotein cholesterol to construct a fibrosis MASH evaluation prediction model for obese people, which has better evaluation performance.

The invention relates to the field of biological medicine, in particular to a whole blood quality control product which comprises mixed hydroformylated red blood cells, protection liquid and plasma. The preparation method of the hydroformylated red blood cells comprises the following steps: pre-immobilizing red blood cells through non-crosslinked aldehyde, and then mainly immobilizing the red blood cells through crosslinked aldehyde; a quality control standard substance is also added into the whole blood quality control product, and the quality control standard substance is one or more of cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein, blood sugar and uric acid. Compared with the prior art, the whole blood quality control product has the advantages of low red blood cell hemolysis rate and longer shelf life.

A herbal composition for the treatment of a variety of metabolic disorders in mammals, especially human beings, is disclosed. A method of preparing the herbal composition is also disclosed. The herbal composition treats and alleviates a plurality of metabolic disorders, including central obesity, high blood pressure levels, high blood sugar levels, stress-induced fatigue, and type 2 diabetes. The herbal composition comprises the extracts of Dolichos lablab, Achyranthes aspera, and at least one of Cinnamomum zeylanicum and Cinnamomum cassia. The aforementioned extracts are present in the herbal composition at a predetermined weight range. The aforementioned extracts are standardized to contain active compounds, including proanthocyanidins, saponins, polyphenols, and tannins, in a predetermined concentration and in predetermined purity levels. The herbal composition causes an enhancement of adiponectin levels and high-density lipoprotein (HDL) levels, and a reduction in the accumulation of adipose tissue, total cholesterol levels, triglyceride levels, and low-density lipoprotein (LDL) levels.

The present invention relates to a recombinant high density lipoprotein nanoparticle comprising cholesterol and a composition for preventing or treating Alzheimer's disease and cancer comprising the same. Specifically, the cholesterol-containing recombinant high-density lipoprotein nanoparticles of the present invention have an excellent cell introduction rate, promote the outflow of cholesterol from cells, and thus have a cancer cell killing effect, and thus can be used for the prevention or treatment of cancer.